7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Belite Bio, Inc
(NASDAQ:BLTE) 

BLTE stock logo

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.

Founded: 2016
IPO Price: $6 (Apr 29, 2022)
CEO / Founder: Dr. Tom Lin 
Sector: Technology
Industry: General

Share this website to your friends
Belite Bio Op Cashflow Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -02.525.047.5510.0712.5915.1117.63Thousand
Belite Bio Free Cashflow Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -02.65.217.8110.4213.0215.6318.23Thousand
Belite Bio Cash Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -64.75-55.5-46.25-37-27.75-18.5-9.250Thousand
Belite Bio (GAAP) P/E ratio ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -259.97-222.83-185.69-148.55-111.41-74.28-37.140
Belite Bio P/B ratio ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -47.73-37.48-27.22-16.96-6.73.5513.8124.07
No extra charts and metrics for this ticker.